Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis.
OBJECTIVE
Patients with progressive familial intrahepatic cholestasis (PFIC) type 3 have a mutation in the MDR3 gene, encoding the hepatocanalicular phospholipid translocator. In general, liver failure develops within the first decade of life in these patients. Previous studies have shown that in the mdr2-knockout mouse, the animal model for this disease, the absence of phospholipids in bile causes chronic bile salt-induced damage to hepatocytes. We aimed to test the efficacy of hepatocyte transplantation and liver repopulation in this disease model.


METHODS
Transgenic MDR3-expressing hepatocytes as well as normal mdr2(+/+) hepatocytes were transplanted in mdr2(-/-) mice, and liver repopulation was assessed by immunohistochemistry and measurement of biliary lipid secretion.


RESULTS
Transplanted hepatocytes partially repopulated the liver, restored phospholipid secretion, and diminished liver pathology. Repopulation was stronger when hepatocellular damage was enhanced by a bile salt-supplemented diet. After 1 year, however, these animals developed multiple hepatic tumors, and biliary phospholipid secretion decreased. In transplanted animals receiving a control diet, repopulation was slower but eventually remained stable at 21%, while liver pathology was completely abrogated and tumor formation was prevented.


CONCLUSIONS
These results suggest that moderate liver pathology is a safe condition for the induction of effective hepatocyte repopulation and that this therapy is potentially applicable to patients with PFIC type 3.
De Vree
J M
JM
Laboratory for Experimental Hepatology, Academic Medical Center, Amsterdam, The Netherlands.
Ottenhoff
R
R
Bosma
P J
PJ
Smith
A J
AJ
Aten
J
J
Oude Elferink
R P
RP
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000235:genetics; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000818:Animals; D020355:Cholates / Q000008:administration & dosage / Q000494:pharmacology; D002779:Cholestasis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D004032:Diet; D022781:Hepatocytes / Q000637:transplantation*; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D008297:Male; D051379:Mice; D018345:Mice, Knockout / Q000235:genetics; D008822:Mice, Transgenic / Q000235:genetics; D010743:Phospholipids / Q000378:metabolism
D018435:ATP Binding Cassette Transporter, Subfamily B; D018528:ATP-Binding Cassette Transporters; D020355:Cholates; D010743:Phospholipids; C095122:multidrug resistance protein 3